Artificial intelligence can revolutionize drug discovery by expediting development, reducing costs, and improving treatment options, but addressing its limitations is crucial for future success.
Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Despite advancements in umbilical cord blood transplants, social determinants of health, such as poverty and public insurance, continue to impact outcomes, underscoring the need for equitable access to lifesaving treatments.
Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV population and people with HIV who are heavily treated with those have experienced less treatment.
The progress made to mitigate the opioid use crisis still pales in comparison with the crucial effort needed to address it, especially in regard to accessing medication.